CVS
CVS Health
Health Care · Health Care Services · US
$95.93
Data: 2026-05-15
✓ ETHICAL PASS

WEAK MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$123.2B
Total market value of the company
42.36
Expensive — high growth expected
11.55
Based on estimated future earnings — lower means cheaper
Rev Growth
+6.1%
Year-over-year revenue change
Profit Margin
0.7%
How much profit the company keeps from each dollar of revenue
3.8%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$101.58
+6% from current price — median analyst estimate
Recommendation
STRONG_BUY
Consensus view from 26 analysts covering this stock
About CVS Health

CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

https://www.cvshealth.com

Country: United States Employees: 219,000 Industry: Healthcare Plans
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
31.5% PASS
Debt must be below 33% of total assets
Cash Ratio
10.5% PASS
Interest-bearing cash below 33% of assets
Receivables
9.8% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
$100.35
What our model estimates this business is worth per share
4.4%
Slight discount to fair value
Rating
FAIR VALUE
Overall assessment combining ethics, valuation, and quality
94.7th
Ranks in the top 5% of our 13,571 screened universe
Ethical Score
81.6
Valuation Score
77.5
Quality Score
38.3
Combined
69.1

Trading near fair value at $97 (estimated $100). Passes all ethical screens. Ranks better than 88% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKUP
Price trending up with increasing momentum
1.053
Excellent risk-adjusted returns
0.0980
Suggested allocation is meaningful — the edge justifies a position
1.041
Returns exceed worst-case losses — strong risk profile
Annual Return
35.8%
Historical annualised return based on price data
-34.4%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
13
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.59
Less volatile than the market — more defensive
52W High
$98.43
3% below the year high
52W Low
$58.50
64% above the year low
Avg Volume
8,058,998
Average daily shares traded — higher means easier to buy and sell
2.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
1.4%
Low short interest — limited bearish positioning
2.7%
Annual dividend as a percentage of the share price
$2.28
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

1.01
Meaningful debt load — monitor closely
0.87
Below 1 means short-term obligations exceed liquid assets — risk flag
Quick Ratio
0.61
Like current ratio but excludes inventory — stricter test
Gross Margin
13.4%
Revenue left after cost of goods — higher means pricing power
Operating Margin
4.1%
Profit from core operations before interest and tax
$5.2B
Positive — the business generates more cash than it spends
Revenue (TTM)
$405.6B
Total revenue over the last 12 months
Net Income
$2.9B
Profitable — the bottom line is positive
Analyst Coverage
Analysts
26
Target High
$140.00
Target Median
$101.58
Target Low
$79.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-21 ROBBINS LARRY Director 3,372,000 $317,471,136
2026-05-14 NORWALK LESLIE V Director 1,447 $140,576
2026-05-14 BALSER JEFFREY R M.D., PH.D. Director 2,058 $199,935
2026-05-14 SANSONE GUY P Director 1,447 $140,576
2026-05-14 AGUIRRE FERNANDO Director 1,563 $151,845
2026-05-14 BROWN C DAVID II Director 1,544 $150,000
2026-05-14 KIRBY JOHN SCOTT Director 1,447 $140,576
2026-05-08 MANDADI TILAK Officer 69,551 $6,230,379
2026-03-31 KHICHI SAMRAT S General Counsel 12,531 $899,976
2026-03-31 CAPOZZI HEIDI B Officer 10,025 $719,996
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Ro Khanna Democrat Purchase 1K–15K
2025-11-21 Dwight Evans Democrat Sale 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.